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RESEARCH ARTICLE
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Abstract
Introduction: A previous phase 2b study supported the use of the 5-HT6 receptor
antagonist intepirdine as adjunctive therapy to donepezil for Alzheimer’s disease (AD)
dementia. A phase 3 study, MINDSET, was performed to test this hypothesis.
Methods: MINDSET was a global, double-blind, randomized, placebo-controlled trial
in 1315 mild-to-moderate AD dementia patients on stable donepezil. Patients received
35 mg/day intepirdine or placebo for 24 weeks. The co-primary endpoints were change
from baseline to week 24 on the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and Alzheimer’s Disease Cooperative Study-Activities of Daily Living
(ADCS-ADL).
Results: There were no statistically significant differences between intepirdine
and placebo groups (adjusted mean [95% confidence interval]) on the co-primary
endpoints ADAS-Cog (−0.36 [−0.95, 0.22], P = 0.2249) and ADCS-ADL (−0.09 [−0.90,
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0.72], P = 0.8260). Intepirdine demonstrated a favorable safety profile similar to
placebo.
Discussion: Intepirdine as adjunctive therapy to donepezil did not produce statistical
improvement over placebo on cognition or activities of daily living in mild-to-moderate
AD dementia patients.
KEYWORDS

5-HT6, Alzheimer’s disease, clinical trial, intepirdine, phase 3

1

INTRODUCTION

Sum of Boxes (CDR-SB;9 P = 0.462). The 35 mg/day group achieved significance over placebo on the CDR-SB at week 12, but not at later time-

Alzheimer’s disease (AD) is a progressive neurodegenerative disor-

points, although numerical advantage was maintained at weeks 24, 36,

der characterized by deterioration of memory, cognition, and the

and 48. Treatment with 35 mg/day intepirdine also demonstrated a sig-

ability to perform daily tasks. AD is the most common cause of

nificant benefit versus placebo at week 24 on the secondary endpoint

dementia in adults and causes a massive global health burden that

23-item Alzheimer’s Disease Cooperative Study-Activities of Daily Liv-

is expected to worsen substantially in the coming decades. The

ing (ADCS-ADL;10 P = 0.033). In Study 866 and all other phase 2 AD

four currently available AD medications produce only modest cogni-

trials, 35 mg/day intepirdine was well tolerated.3,7

tive improvement, highlighting the urgent need for novel treatment
approaches.1

The beneficial effects observed in Study 866 provided sufficient
rationale for intepirdine’s continued development. At the same time,

Deficiencies in neurotransmitters, particularly acetylcholine,

another 5-HT6 receptor antagonist, idalopirdine, had demonstrated

are a key feature in the pathophysiology of AD dementia. Acetyl-

statistically significant benefit as an adjunct to donepezil in a separate

cholinesterase inhibitors (AChEIs: donepezil, galantamine, and

phase 2 AD dementia trial, providing additional support for intepir-

rivastigmine) can improve AD symptoms by preventing synaptic

dine’s mechanism of action.11 Here, we report the results of a phase

acetylcholine breakdown in the

brain.2

However, AChEI benefits are

3 clinical trial of intepirdine (MINDSET). The primary study objec-

limited, possibly because dosing is restricted by peripheral cholinergic

tives were to determine the effects of 35 mg/day intepirdine versus

stimulation, which induces several side effects.3

placebo on cognition and activities of daily living in mild-to-moderate

Targeting the serotonin (5-hydroxytryptamine) subtype 6 (5-HT6)

AD dementia patients on background donepezil.

receptor, which is located primarily in brain regions critical to memory and learning, has garnered significant interest as a therapeutic
mechanism in AD. Inhibition of the 5-HT6 receptor has been shown

2

METHODS

to increase neuronal release of acetylcholine, as well as other neurotransmitters that are dysregulated in AD, leading to cognitive improve-

2.1

Trial design

ment in preclinical models.3,4 Because the 5-HT6 receptor is located
almost exclusively in the central nervous system, 5-HT6 antagonism

MINDSET was a multicenter, double-blind, randomized, placebo-

has the potential to increase central acetylcholine release, while min-

controlled, parallel-group study in patients with mild-to-moderate AD

This mechanism is distinct and com-

dementia who were on stable donepezil. The efficacy and safety of

plementary to that of the AChEIs, supporting adjunctive use to enhance

35 mg intepirdine versus placebo administered orally once daily was

therapeutic benefit.

evaluated over a 24-week treatment period. A total of 207 clinical

imizing peripheral side

effects.3,4

Intepirdine (also called RVT-101 or SB-742457), a potent 5-HT6

sites were initiated across 19 countries (Argentina, Australia, Bulgaria,

receptor antagonist, is an orally administered small molecule that has

Canada, Chile, Croatia, Czech Republic, France, Germany, Italy, Poland,

been studied in four phase 2 clinical trials in patients with mild-to-

Serbia, Singapore, Slovakia, Spain, Republic of Korea, Taiwan, United

moderate AD dementia. Mixed or negative results were seen when

Kingdom, United States). The Protocol, the Statistical Analysis Plan,

in three of the trials.5–7

and an Addendum to the Statistical Analysis Plan written in response

In contrast, the most encouraging results were observed in the fourth

to European Medicines Agency comments are provided in Support-

trial, which was a large phase 2b study (N = 684) administering intepir-

ing Information. The study was reviewed and approved by a national,

dine as an adjunct to donepezil (Study 866).7 Study 866 demonstrated

regional, or investigational independent ethics committee or institu-

statistically significant superiority of 35 mg/day intepirdine over

tional review board for each clinical site. An independent safety moni-

placebo at week 24 on the co-primary endpoint 11-item Alzheimer’s

toring committee reviewed safety data on an ongoing basis. A list of site

Disease Assessment Scale-Cognitive Subscale (ADAS-Cog;8 P = 0.012),

investigators and safety monitoring committee members is provided in

but not on the co-primary endpoint Clinical Dementia Rating Scale-

Supporting Information. The study was conducted in accordance with

intepirdine was administered as monotherapy
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the principles of Good Clinical Practice and the Declaration of Helsinki.
This trial is registered with ClinicalTrials.gov, NCT02585934.

RESEARCH IN CONTEXT
1. Systematic Review: We searched PubMed with terms

2.2

“5-HT6 receptor antagonist” AND “Alzheimer’s dis-

Patients

ease.” We identified two 5-HT6 receptor antagonists
MINDSET included patients who (1) met the criteria for a clinical diag-

(intepirdine and idalopirdine) that had demonstrated

nosis of AD dementia in accordance with the recommendations from

statistically significant improvements on the Alzheimer’s

the National Institute on Aging-Alzheimer’s Association workgroups;12

Disease Assessment Scale-Cognitive Subscale (ADAS-

(2) had a magnetic resonance imaging (MRI) or computed tomogra-

Cog) when administered as an adjunct to donepezil in

phy (CT) scan consistent with the exclusionary diagnosis of AD and

phase 2 trials. MINDSET was the first phase 3 study of

performed during screening or within 12 months before screening; (3)

intepirdine and sought to corroborate the previous phase

were between 50 and 85 years of age, inclusive; (4) had a Mini-Mental

2 results.

State Examination (MMSE) score of 12 to 24, inclusive, at screening and

2. Interpretation: 35 mg/day intepirdine as adjunctive ther-

a score of 10 to 26, inclusive, at baseline (range 0 to 30, higher score

apy to donepezil failed to demonstrate statistically sig-

indicates lower impairment);13 (5) had a modified Hachinski Ischemic

nificant improvement versus placebo on the co-primary

score ≤4 at screening (range 0 to 12, higher score indicates greater

endpoints ADAS-Cog and Alzheimer’s Disease Cooper-

and (6) had a documented history of at least 4

ative Study-Activities of Daily Living over 24 weeks. A

months of ongoing donepezil therapy, with at least 2 months of stable

statistical benefit over placebo was observed on the key

dosing (5 or 10 mg/day) and with no intent to change during the study.

secondary endpoint Clinician’s Interview-Based Impres-

Patients were excluded if they (1) showed evidence of dementia not

sion of Change plus caregiver interview. Intepirdine

related to AD; (2) had a history of significant neurological or psychiatric

was well tolerated with a safety profile comparable to

illness; (3) had a history of negative amyloid positron emission tomog-

placebo.

degree of

ischemia);14

raphy (PET) scan (n.b. amyloid scan was not required); (4) were tak-

3. Future Directions: New research into Alzheimer’s dis-

ing memantine, AChEIs other than donepezil, or other agents to treat

ease heterogeneity as well as the functionality of the

cognitive impairment; or (5) exhibited unacceptable laboratory values.

5-HT6 receptor and its ligands may help elucidate the

Before study participation, informed consent or assent was obtained

underlying reasons behind the conflicting data observed

from all patients and caregivers.

to date between the phase 2 and 3 trials.

2.3

Randomization and blinding

Patients were randomized in a 1:1 ratio to receive 35 mg/day intepir-

treatment period. Patients who completed the last on-treatment visit

dine or placebo, with all patients maintaining their pre-study stable

of MINDSET were eligible to enroll in an open-label extension study

donepezil dose. Randomization was performed using a validated inter-

(NCT02586909). Patients who did not enter the extension study had

active voice/web response system, with block sizes of four. Random-

a follow-up safety visit at week 26. During the run-in period, patients

ization was stratified by patients’ baseline MMSE scores (20%–30%:

received single-blinded placebo and their pre-study donepezil dose to

MMSE 10–15; 40%–60%: MMSE 16–20; 20%–30%: MMSE 21–26).

evaluate the variability of their baseline status. During the double-blind

This stratification methodology replicated that of Study 866 and was

treatment period, patients received 35 mg/day intepirdine or placebo

chosen because baseline AD severity has been correlated with extent

in addition to their background donepezil. Pill count was monitored to

of clinical decline and the investigational drug could have differen-

assess compliance.

tial effects based on patient severity. The randomization sequence

Scheduled visits were at weeks 3, 6, 12, 18, and 24 during the

was generated by an independent statistician who had no further

double-blind treatment period. The co-primary endpoint assessments,

involvement with the study. Study staff, patients, and caregivers were

ADAS-Cog and ADCS-ADL, were performed at each visit, except

blinded to treatment group assignment. Intepirdine and placebo were

screening. The first key secondary assessment Clinician’s Interview-

identical in tablet appearance and packaging to ensure adequate

Based Impression of Change plus caregiver interview (CIBIC+)15 was

blinding.

performed at weeks 12, 18, and 24 and was rated relative to a Clinician’s Interview-Based Impression of Severity (CIBIS) administered at
baseline. The CIBIC+ and CIBIS were assessed by a rater indepen-

2.4

Procedures

dent of other efficacy outcomes. The second key secondary assessment
Dependence Scale (DS)16 was performed at baseline and at week 24.

The study consisted of a 4-week screening period, a 3-week single-

All raters passed a rigorous qualification and certification process. Vari-

blind placebo run-in period, and a 24-week randomized double-blind

ability and rating errors were monitored in a blinded manner.

4 of 9
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Outcomes

The co-primary endpoints were (1) ADAS-Cog score change from
baseline to week 24 (range 0 to 70, higher score indicates worse
function) and (2) ADCS-ADL score change from baseline to week 24
(range 0 to 78, higher score indicates better function). Pre-specified
key secondary endpoints were (1) CIBIC+ score at week 24 (range 0
to 7, higher score indicates worsened function from baseline) and (2)
DS Total Score change from baseline to week 24 (range 0 to 15, higher
score indicates higher dependency and worse function). Other efficacy
endpoints included change from baseline to week 24 on the Neuropsychiatric Inventory (NPI) Total Score17 and ADAS-Cog plus delayed
word recall and total digit cancellation score (ADAS-Cog-13).18
Safety endpoints included treatment-emergent adverse events
(TEAEs); physical examinations; suicidality assessments; and measurements of vital signs, electrocardiograms, and laboratory tests. TEAEs
were coded using the Medical Dictionary for Regulatory Activities
(MedDRA).

2.6

Statistical analysis

Sample size estimates were based on the results of Study 866, which
demonstrated an ADAS-Cog difference between treatment groups of

F I G U R E 1 Patient flow through the MINDSET study. A total of
1315 patients were randomized across 19 countries. A total of 1307
patients were included in the safety population, and 1276 patients
were included in the modified intent-to-treat (mITT; efficacy)
population

1.5 points (standard deviation [SD] 6) and an ADCS-ADL difference of
1.9 points (SD 9).7 At a two-sided 0.05 significance level, we calculated

given the negative results on the co-primary endpoints. All analyses

that 435 patients per arm would allow a difference of 1.6 points (SD

were performed using SAS software, version 9.4. The Statistical Anal-

6.5) to be detected on the ADAS-Cog with 95% power and a difference

ysis Plan and Addendum were finalized prior to unblinding the treat-

of 2 points (SD 9) to be detected on the ADCS-ADL with 90% power.

ment allocation codes.

Assuming a drop-out/missing data rate of ≈25%, 1150 patients were
planned to be randomized.
The safety population consisted of all patients who received at least

3

RESULTS

one dose of double-blind study medication. The primary population for
efficacy analysis consisted of all randomized patients who took at least

MINDSET randomized patients between October 21, 2015 and March

one treatment dose and had at least one baseline and one post-baseline

8, 2017. A total of 2173 patients were screened, and 1315 patients

primary efficacy assessment (modified intent-to-treat [mITT] popula-

were randomized (Figure 1). The primary reason for unsuccessful

tion).

screening (observed in 296 patients) was a failure to meet the MMSE

Treatment comparisons of the co-primary endpoints were based on

score inclusion criteria. A total of 654 patients received placebo,

the Observed Case dataset (no imputation for missing values) using

and 661 patients received 35 mg/day intepirdine, with 581 placebo-

a mixed model for repeated measures (MMRM) with restricted max-

treated and 592 intepirdine-treated patients completing the study

imum likelihood estimation and an unstructured covariance matrix.

through week 24. Patient withdrawal rates were similar between

Countries were grouped into five regions for analysis. The statisti-

placebo (11.2%) and intepirdine (10.4%) groups. The safety popula-

cal model was fitted with terms for treatment group, visit, treatment

tion (n = 1307) comprised 651 placebo-treated patients and 656

by visit interaction, baseline score, baseline MMSE, baseline score by

intepirdine-treated patients. The mITT population (n = 1276) com-

visit interaction, and region. The interaction term of baseline MMSE

prised 633 placebo-treated patients and 643 intepirdine-treated

by visit was evaluated at the 10% level of significance. If the interac-

patients.

tion term was found to be significant, it was included in the MMRM

Demographics, baseline characteristics, regional distributions, and

model. Primary inferences were drawn from treatment differences for

donepezil dose distributions were similar between treatment groups

the changes from baseline derived from the MMRM models at week 24.

(Table 1). Average age at diagnosis of probable AD dementia was 70.2

Adjusted means and 95% confidence intervals (CI) are presented.

years, and patients were diagnosed a median of 2.0 years prior to

All hypothesis tests were two-sided at a significance level of 0.05.

screening. The average baseline MMSE score of 18.5 points for each

Efficacy would be concluded only if both primary endpoints showed

treatment group reflected the stratified design of the study and a popu-

a significant drug–placebo difference. Nominal P-values are reported,

lation with mild-to-moderate AD dementia. Baseline efficacy endpoint

5 of 9

LANG ET AL .

TA B L E 1 Demographics and baseline characteristics of the mITT
population (N = 1276)

(adjusted mean difference = −0.09 versus placebo, 95% CI [−0.90,
0.72], P = 0.8260).
For the CIBIC+, the intepirdine group was numerically superior

Placebo
(N = 633)

Intepirdine
(N = 643)

to placebo at the 18- and 24-week timepoints, with the difference

Age (years), mean (SD)

72.5 (7.55)

72.7 (7.68)

at 24 weeks achieving statistical significance (adjusted mean differ-

Age (years) at diagnosis, mean (SD)

70.0 (7.70)

70.4 (7.75)

ence = −0.12 versus placebo, 95% CI [−0.22, −0.02], P = 0.0234;

Time (years) since diagnosis, mean (SD)

2.62 (2.05)

2.55 (2.25)

Table 2, Figure 3). This result was largely consistent across subgroup
and sensitivity analyses. There was no statistical benefit at week 24

Female sex, n (%)

394 (62.2%)

386 (60.0%)

White race, n (%)

592 (94.1%)

595 (93.1%)

Non-Hispanic ethnicity, n (%)

519 (82.8%)

518 (81.2%)

US

169 (26.7%)

171 (26.6%)

yses generally showed no meaningful differences between treatment

Non-US English

132 (20.8%)

133 (20.7%)

groups; however, there was evidence that patients who were taking

West Europe

115 (18.2%)

110 (17.1%)

donepezil the longest prior to study entry (i.e., greater than the mean)

East Europe

117 (18.5%)

116 (18.0%)

experienced statistical improvement on the ADAS-Cog with interpir-

Rest of World

100 (15.8%)

113 (17.6%)

Region, n (%)

versus placebo, 95% CI [−0.07, 0.32], P = 0.2096). Other secondary
endpoints were not statistically significant versus placebo (Table 2).
Non-CIBIC+ subgroup analyses and exploratory post hoc efficacy anal-

dine versus placebo.
The incidence of TEAEs, treatment-emergent serious adverse

MMSE score
Mean (SD)

over placebo for the DS Total Score (adjusted mean difference = 0.12

events (SAEs), and TEAEs leading to withdrawal were similar across
18.5 (3.63)

18.5 (3.70)

10–15

151 (24.0%)

148 (23.0%)

TEAEs (≥2% in either treatment group) were fall, urinary tract infec-

16–20

284 (44.9%)

283 (44.0%)

tion, nasopharyngitis, headache, dizziness, diarrhea, nausea, back pain,

21–26

197 (31.1%)

212 (33.0%)

bronchitis, and cough. Almost all TEAEs were reported at an incidence

Stratification, n (%)

treatment groups (Table 3). TEAEs were generally consistent with
those expected for the trial’s patient population. The most common

of <5%. Suicidal ideation and behavior were also low and compara-

Donepezil dosing, n (%)
5 mg/day

151 (23.9%)

142 (22.1%)

10 mg/day

482 (76.1%)

501 (77.9%)

ADAS-Cog, mean (SD)

24.8 (8.80)

24.3 (8.87)

ADCS-ADL, mean (SD)

57.7 (12.6)

58.1 (12.7)

CIBIS, mean (SD)

3.8 (0.76)

3.7 (0.74)

DS Total Score, mean (SD)

5.20 (2.34)

4.90 (2.34)

NPI Total Score, mean (SD)

7.60 (9.59)

7.70 (9.88)

ADAS-Cog-13, mean (SD)

37.0 (10.3)

36.5 (10.4)

Notes: The treatment groups were comparable with respect to the distributions of baseline characteristics. Regions were pre-specified for subgroup analyses per the stratifications in the table. US = United States;
Non-US English = United Kingdom, Canada, Australia; West Europe = Germany, Spain, Italy, France; East Europe = Bulgaria, Croatia, Czech Republic, Poland, Serbia, Slovakia; Rest of World = Argentina, Chile, Singapore,
Republic of Korea, Taiwan
Abbreviations: ADAS-Cog, Alzheimer’s Disease Assessment ScaleCognitive Subscale; ADCS-ADL, Alzheimer’s Disease Cooperative StudyActivities of Daily Living; CIBIS, Clinician’s Interview-Based Impression of
Severity; DS, Dependence Scale; NPI, Neuropsychiatric Inventory; mITT,
modified intent-to-treat; SD, standard deviation.

ble across groups. Increased incidence of elevated liver enzymes has
been observed in the active group of other 5-HT6 receptor antagonist
studies;11,19 this trend was not seen in MINDSET. No death was considered related to study treatment by the site investigator.

4

DISCUSSION

The primary objectives of the phase 3 MINDSET study were not met:
35 mg/day intepirdine as adjunctive therapy to donepezil in mildto-moderate AD dementia patients did not show statistically significant benefit over placebo on the co-primary endpoints ADAS-Cog and
ADCS-ADL over the 24-week treatment period. The intepirdine group
demonstrated a statistically significant benefit over placebo on the
first key secondary endpoint CIBIC+ at 24 weeks (P = 0.0234). The
second key secondary endpoint DS Total Score, as well as all other
secondary endpoints, showed no significant difference between treatment groups. Intepirdine demonstrated a strong safety profile during
the 24-week treatment period, with no apparent safety differences
compared to placebo.
The CIBIC+, a measure of global functioning encompassing both

values were similar between treatment groups. Almost all patients

cognition and activities of daily living, has been used as a co-primary

were considered compliant with study drug and donepezil.

endpoint and measure of clinical meaningfulness in studies of all cur-

The results of the co-primary endpoint analyses are shown in Fig-

rently available AD medications.20–23 In MINDSET, it was assessed

ure 2A,B and Table 2. Intepirdine 35 mg/day as adjunctive therapy

by experienced clinicians independent of other efficacy variables to

to donepezil failed to demonstrate statistically significant differences

reduce bias. The treatment benefit of 0.12 points observed in this study

from placebo on the ADAS-Cog (adjusted mean difference = −0.36

is more modest than the 0.2- to 0.5-point improvements seen in piv-

versus placebo, 95% CI [−0.95, 0.22], P = 0.2249) and ADCS-ADL

otal studies of approved AD medications20–23 as well as the statistically
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F I G U R E 2 Adjusted mean changes on the co-primary endpoints, (A) Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)
and (B) Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scores, over the 24-week treatment period (modified
intent-to-treat [mITT] population). Treatment comparisons were based on a mixed model for repeated measures. Error bars are 95% confidence
intervals.

TA B L E 2

Primary and secondary efficacy outcomes at end of double-blind treatment period, week 24 (mITT population)
Adjusted mean through week 24
n

Placebo

n

Pairwise comparison
Intepirdine

Difference

95% CI

P-value

Primary endpoints
ADAS-Cog change from baseline

577

0.75 (0.21)

584

0.39 (0.21)

−0.36 (0.30)

−0.95, 0.22

0.2249

ADCS-ADL change from baseline

575

−0.97 (0.29)

588

−1.06 (0.29)

−0.09 (0.41)

−0.90, 0.72

0.8260

−0.22, −0.02

0.0234

Secondary endpoints
CIBIC+

568

4.30 (0.037)

577

4.18 (0.037)

−0.12 (0.051)

DS Total Score change from baseline

568

0.17 (0.071)

580

0.30 (0.070)

0.12 (0.10)

-0-.07, 0.32

0.2096

NPI Total Score change from baseline

570

0.06 (0.34)

583

−0.08 (0.34)

−0.14 (0.48)

−1.09, 0.80

0.7650

ADAS-Cog-13 change from baseline

576

0.64 (0.24)

583

0.26 (0.23)

−0.38 (0.33)

−1.03, 0.27

0.2472

A total of 633 placebo-treated patients and 643 intepirdine-treated patients made up the mITT population. The co-primary endpoints, ADAS-Cog and ADCSADL, and the secondary endpoints, DS Total Score, NPI Total Score, and ADAS-Cog-13, were not statistically different between the intepirdine and placebo
groups. The secondary endpoint CIBIC+ demonstrated a statistically significant improvement favoring intepirdine over placebo. Treatment comparisons
were based on a mixed model for repeated measures. SE are in parentheses. n = number of patients with measurement of the indicated endpoint at week 24
Abbreviations: ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive Subscale; ADCS-ADL, Alzheimer’s Disease Cooperative Study-Activities of Daily
Living; CIBIC+, Clinician’s Interview-Based Impression of Change plus caregiver interview; DS, Dependence Scale; NPI, Neuropsychiatric Inventory; mITT,
modified intent-to-treat; SE, standard error.

significant 0.31-point improvement observed in a previous monother-

to detect treatment effects on both co-primary endpoints. Despite this

apy study of intepirdine.5 In Study 866, a different measure of global

increased power and the fact that the baseline characteristics of the

functioning (CDR-SB) was used, and the result for the 35 mg/day group

two studies were largely comparable, MINDSET failed to corroborate

was statistically significant at week 12 and non-significantly different

the results of Study 866.

but numerically superior to placebo at weeks 24, 36, and 48.7 Over-

Study-to-study variability in AD trials is not uncommon. Idalopir-

all, the benefit of intepirdine on AD global function is unclear, and any

dine, a selective 5-HT6 receptor antagonist, and latrepirdine, an anti-

effect size would likely be smaller than that of currently approved med-

histamine capable of non-selectively antagonizing the 5-HT6 recep-

ications.

tor, followed a similar development pattern to intepirdine. Idalopir-

MINDSET’s co-primary endpoints, sample size, and intepirdine dose

dine demonstrated a statistical benefit on the ADAS-Cog in a phase

were selected based on the results of Study 866. Although MIND-

2 study but then failed to meet the same endpoint in three separate

SET required a donepezil use history of only 4 months compared to

phase 3 trials, although these studies used different dose regimens

6 months in Study 866, the eligibility criteria of MINDSET generally

than the phase 2 study.11,19 Latrepirdine showed positive results on

matched that of Study 866. The sample size per arm of MINDSET was

multiple endpoints in phase 2 but failed on these endpoints in two

almost three times that of Study 866, so MINDSET was well powered

larger phase 3 studies using an identical dose.24 Interestingly, in both
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development programs, the phase 3 studies’ primary endpoint placebo
declines from baseline were lower than the declines in the phase 2
studies.11,19,24 Similarly, placebo declines in MINDSET were lower than
Study 866 (ADAS-Cog at week 24: 0.75-point decline in MINDSET versus 1.2-point decline in Study 866; ADCS-ADL at week 24: 0.97-point
decline in MINDSET versus 3.2-point decline in Study 866).7 Because
the placebo group did not act as predicted, separation between treatment groups was difficult to achieve.
The major difference between Study 866 and MINDSET was
MINDSET’s considerably larger geographical scope. Similar to other
global AD trials,25,26 MINDSET demonstrated striking heterogeneity across regions in placebo change from baseline to week 24 on
the co-primary endpoints, with one region (“Rest of World,” i.e.,
F I G U R E 3 Adjusted means of key secondary endpoint Clinician’s
Interview-Based Impression of Change plus caregiver interview
(CIBIC+) over 24-week treatment period (modified intent-to-treat
[mITT] population). Scores between 0 and 4 indicate an improvement
in global function from baseline, while scores between 4 and 7 indicate
a decline from baseline. Treatment comparisons were based on a
mixed model for repeated measures. Error bars are 95% confidence
intervals

Argentina, Chile, Republic of Korea, Singapore, Taiwan) even experiencing mean improvements (ADAS-Cog placebo change range: −1.19
to 1.85; ADCS-ADL placebo change range: 1.11 to −3.37). Although all
nine countries involved in Study 866 were included in MINDSET, the
regional distribution within each study differed substantially. A total of
52% of dosed patients in Study 866 were recruited from West Europe
(data unpublished), a region shown to produce relatively large placebo
declines,25,26 compared to only 17.7% in MINDSET. Thus, MINDSET’s
increased regional heterogeneity may have resulted in its lower-than-

TA B L E 3

Adverse events seen in safety population (N = 1307)

At least one TEAE, n (%)

expected placebo decline, potentially contributing to the study’s failure
as the investigational drug could have affected non-progressing and

Placebo
(N = 651)

Intepirdine
35 mg
(N = 656)

355 (54.5%)

366 (55.8%)

tively recruit in regions with experienced sites and raters and a well-

fast-progressing patients differently.
Given their smaller size, phase 2 AD trials may be able to selec-

Fall

29 (4.5%)

37 (5.6%)

characterized, progressive patient population. For phase 3 AD trials,

Urinary tract infection

26 (4.0%)

25 (3.8%)

sponsors often decide to recruit in new regions to increase the study’s

Nasopharyngitis

19 (2.9%)

23 (3.5%)

sample size/power and complete the study in a timely manner. How-

Headache

18 (2.8%)

17 (2.6%)

Dizziness

12 (1.8%)

19 (2.9%)

Diarrhea

17 (2.6%)

17 (2.6%)

Nausea

13 (2.0%)

17 (2.6%)

harder to accomplish, and the underlying disease characteristics of the

Back pain

15 (2.3%)

11 (1.7%)

study’s patient population may change.25–27 Therefore, while initially

Bronchitis

10 (1.5%)

14 (2.1%)

well conceived, the decision to expand to new geographies may reduce

Cough

7 (1.1%)

15 (2.3%)

probability of success and phase-to-phase translatability. Future large-

Elevated liver enzymes

9 (1.5%)

7 (1.1%)

scale AD trials may benefit from restricting recruitment to well-studied

Treatment-emergent SAE,
n (%)

44 (6.8%)

40 (6.1%)

regions or periodically assessing placebo decline through a data moni-

TEAE leading to study
withdrawal, n (%)

21 (3.2%)

Death, n (%)

2 (0.3%)

ever, this decision may introduce significant treatment, operational,
and/or disease heterogeneity because new medical systems with different standards of care are added, executional standardization across
sites and raters with varying linguistic and cultural backgrounds is

toring committee.
21 (3.2%)

In addition, although the patients in MINDSET met clinical criteria for AD, no biomarker confirmation was required for inclusion into

3 (0.5%)

Notes: All adverse events that occurred in at least 2% of patients in either
treatment group are shown. An increase in the frequency of elevated
liver enzymes has been observed in other 5-HT6 receptor antagonist trials, but, in MINDSET, this TEAE was low and similar across treatment
groups. No deaths were considered to be related to treatment by the study
investigator.
Abbreviations: SAE, serious adverse event; TEAE, treatment-emergent
adverse event.

the study. This approach may have contributed to the reduced placebo
decline observed in the study, as has been documented in other trials
lacking biomarker entry criteria.28 Using biomarker-based strategies
may reduce diagnostic heterogeneity and increase the rate of placebo
decline required for the demonstration of a drug–placebo difference.
Experience with 5-HT6 receptor antagonists in the treatment of AD
has been disappointing and hopes for this class of drugs have diminished. It is possible that underlying factors such as amyloid status and
APOE genotype (neither of which were assessed in MINDSET) affect 5HT6 pharmacodynamics—an area that has not been fully explored so
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far.29 Paradoxically, 5-HT6 receptor agonists have also demonstrated

Eisai, Foresight, GemVax, Genentech, Green Valley, GemVax, Grifols,

pro-cognitive effects, and a better understanding of the 5-HT6 recep-

Hisun, Merck, Otsuka, Resverlogix, Roche, Samumed, Samus, Takeda,

tor and its ligands would help in clarifying the potential of 5-HT6

Third Rock, and United Neuroscience pharmaceutical and assessment

receptor-targeting agents in AD, either alone or in combination with

companies. Jeffrey L. Cummings has stock options in Prana, Neurokos,

an AChEI.3

ADAMAS, MedAvante, QR pharma, BiOasis. Jeffrey L. Cummings owns

Although MINDSET’s per-site enrollment rate (≈0.4 patients per

the copyright of the Neuropsychiatric Inventory. Jeffrey L. Cummings

site per month) was not particularly rapid, the study’s overall enroll-

is supported by KMA; NIGMS grant P20GM109025; NINDS grant

ment rate (≈80 patients per month) was unusually fast for a global

U01NS093334; and NIA grant R01AG053798.

AD trial. We made significant efforts to engage the patient community

Timo Grimmer certifies that there is no actual or potential conflict

across the world and worked closely with study investigators to over-

of interest in relation to this article. Outside the submitted work, Timo

come any operational challenges. For example, while many previous

Grimmer reported having received consulting fees from Actelion, Bio-

AD studies have offered reimbursement for transportation to and from

gen, Eli Lilly, Iqvia/Quintiles, MSD, Novartis, Quintiles, Roche Pharma;

clinical sites, caregivers and study coordinators are burdened with the

lecture fees from Biogen, Lilly, Parexel, Roche Pharma; and grants to his

details of booking drivers and submitting reimbursement paperwork.

institution from Actelion and PreDemTech.

We therefore leveraged a mobile ride-share application, which provided convenient transportation that we easily reimbursed via elec-

Bruno Dubois received fees for his participation in the scientific
advisory board of the study.

tronic billing. We also conducted > 50 presentations at local senior cen-

The institutions of Paul Solomon, Merce Boada, Roy W. Jones, Gio-

ters and engaged grassroots media organizations to discuss the impact

vanni B. Frisoni, Timo Grimmer, and Bruno Dubois received funding for

of AD in their community along with the MINDSET study. Innovative

the conduct of the study.

operational strategies may allow future studies to improve study participants’ satisfaction and reduce time to data readout.
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